Next 10 |
2024-04-08 17:43:47 ET More on Sigma Additive Solutions Financial information for Sigma Additive Solutions Read the full article on Seeking Alpha For further details see: NextTrip files to sell common stock, warrants
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communicat...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...
Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials PR Newswire NEW YORK , Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an e...
Neurotrope ([[NTRP]] -10.4%) and Metuchen Pharmaceuticals completes their previously announced merger following the satisfaction of all closing conditions required by the amended merger agreement.Under the terms of the agreement, Neurotrope shareholders also approved the spin-off of...
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals NEW YORK and MANALAPAN TOWNSHIP, N.J. , Dec. 2, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biop...
Neurotrope’s ([[NTRP]] +3.0%) Board of Directors approved the conditional distribution in connection with the previously announced spin-off of its wholly-owned subsidiary, Neurotrope Bioscience, Inc.Shareholders and certain warrant holders of record of Neurotrope on November 30, 2020, ...
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates Spin-Off Distribution is Conditional Upon the Closing of Neurotrope's Proposed Merger with Metuchen Pharmaceuticals PR Newswire NEW YORK, Nov. 20, 2020 NEW ...
Neurotrope ([[NTRP]]) has dosed the first patient in Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease ((AD)). The study will be conducted in collaboration with the National Institutes of Health ((NIH)) under $2.7M grant to Neurotrope.The 100-subject study, will eval...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communicat...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials PR Newswire NEW YORK , Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an e...